By: J. Kerger MD
The studies in gynaecological cancers presented at this year’s ASCO Annual Meeting, although not reporting breakthrough practice-changing results, are in line with the trend towards targeted therapies witnessed in recent years. In addition to this, several studies confirm the potential of immunotherapy in this setting.
(BELG J MED ONCOL 2015;9:149–53)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
